Previous 10 | Next 10 |
At the American Society of Clinical Oncology (ASCO) Plenary session in December 2022, interim data were presented from the ARC-7 study, which demonstrated a median PFS of ~12.0 months for domvanalimab plus zimberelimab vs 5.4 months for zimberelimab alone. In 2022, Arcus and Gilead in...
Summary Aswath Damodaran is an investing and finance authority on markets & valuation, among many other things. In a 2022 interview, he provided a masterclass in inflation, some lessons in history, and potential ways to protect your portfolio this time around. In a previous piec...
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate at the following upcoming February 2023 virtual investor events: ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eyesonmilan / Shutterstock.com Highlighting the intense competition and sometimes unpredictability of the biopharma space, sector giant Gilead Sciences (NASDAQ: GILD ) stock is down roughly 2% today. While the c...
– 35-45% Reduction in Risk of Progression or Death and a Doubling of mPFS Were Observed in the Domvanalimab-Containing Study Arms, Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC – – With Median Follow-Up of Approximately 12 Months, Both Domva...
Palm Beach, FL – December 1, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer accounts for over 3% of all types of cancers in US. A lethal type of cancer, pancreatic cancer starts in the pancreas of the human body when abnormal cells in the pancre...
– Fourth Interim Analysis Shows Continued Clinically Meaningful Differentiation Across All Efficacy Measures, Including PFS, in Both Domvanalimab-Containing Arms Compared to the Anti-PD-1 Zimberelimab Monotherapy Arm in First-Line NSCLC Patients – – ...
– Fourth Interim Analysis Shows Continued Clinically Meaningful Differentiation Across All Efficacy Measures, Including PFS, in Both Domvanalimab-Containing Arms Compared to the Anti-PD-1 Zimberelimab Monotherapy Arm in First-Line NSCLC Patients – – ...
Summary For the past 6 years, Gilead has been trading in a consistent range between about $60 and $80. Since mid 2018, Gilead has never sustained a share price over $80 for more than a few days. Similarly, the several times that shares have dropped to $58, the price does not r...
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a virtual fireside chat at the upcoming 5 th Annu...
News, Short Squeeze, Breakout and More Instantly...
Arcus Biosciences Inc. Company Name:
RCUS Stock Symbol:
NYSE Market:
Arcus Biosciences Inc. Website:
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Thursday, August 8 th , 2024 at 2 PM...
Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), an investigational small molecule CD73 inhibitor, in Japan and certain oth...
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing di...